retatrutide phase 2 nejm 2023 obesity trial jastreboff Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a The trial that put “24%”

The Mayo Clinic's guidance on GLP-1 medications also emphasizes gradual dose titration to improve tolerability

There are many active substances that can affect the excretion of water and sodium in the kidneys, including BNP, anti-diuretic hormone, and aldosterone

doi: 10.1155/2007/76396 191 TaliazD.StallN.DarD

(Although the approval of the monoclonal antibody teplizumab in 2022, which has recently shown promise as a potential cure for Type 1 diabetes, could cut the rate among all age groups.) As such, while GLP-1s support weight management, they should not be considered a cure-all for overall health or other disease states